1. Welte JW, Barnes GM, Wieczorek WF, et al. Gambling participation in the US—results from a national survey. J Gambl Stud. 2002;18:313-337.
2. Welte JW, Barnes GM, Tidwell MC, Hoffman JH. The prevalence of problem gambling among US adolescents and young adults: results from a national survey. J Gambl Stud. 2008;24:119-133.
3. Potenza MN. Should addictive disorders include non-substance-related conditions? Addiction. 2006; 101(suppl 1):142-151.
4. Tavares H, Gentil V. Pathological gambling and obsessive-compulsive disorder: towards a spectrum of disorders of volition. Rev Bras Psiquiatr. 2007;29:107-117.
5. Johnson EE, Hamer RM, Nora RM. The Lie/Bet Questionnaire for screening pathological gamblers: a follow-up study. Psychol Rep. 1998;83(3, pt 2): 1219-1224.
6. Slutske WS. Natural recovery and treatment-seeking in pathological gambling: results of two US national surveys. Am J Psychiatry. 2006;163:297-302.
7. Sartor CE, Scherrer JF, Shah KR, et al. Course of pathological gambling symptoms and reliability of the Lifetime Gambling History measure. Psychiatry Res. 2007;152:55-61.
8. Johansson A, Grant JE, Kim SW, et al. Risk factors for problematic gambling: a critical literature review. J Gambl Stud. 2009;25:67-92.
9. Dickson-Gillespie L, Rugle L, Rosenthal R, Fong T. Preventing the incidence and harm of gambling problems. J Prim Prev. 2008;29:37-55.
10. Slutske WS, Meier MH, Zhu G, et al. The Australian Twin Study of Gambling (OZ-GAM): rationale, sample description, predictors of participation, and a first look at sources of individual differences in gambling involvement. Twin Res Hum Genet. 2009;12:63-78.
11. Wong PW, Chan WS, Conwell Y, et al. A psychological autopsy study of pathological gamblers who died by suicide. J Affect Disord. 2009 Apr 23; [Epub ahead of print].
12. Weintraub D, Hoops S, Shea JA, et al. Validation of the questionnaire for impulsive-compulsive disorders in Parkinson’s disease. Mov Disord. 2009;24:1461-1467.
13. Steeves TD, Miyasaki J, Zurowski M, et al. Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study. Brain. 2009;132(pt 5):1376-1385.
14. O’Sullivan SS, Evans AH, Lees AJ. Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management. CNS Drugs. 2009; 23:157-170.
15. Hodgins DC, Currie S, el-Guebaly N, Peden N. Brief motivational treatment for problem gambling: a 24-month follow-up. Psychol Addict Behav. 2004;18:293-296.
16. Carlbring P, Smit F. Randomized trial of internet-delivered self-help with telephone support for pathological gamblers. J Consult Clin Psychol. 2008;76: 1090-1094.
17. Petry NM, Weinstock J, Ledgerwood DM, Morasco B. A randomized trial of brief interventions for problem and pathological gamblers. J Consult Clin Psychol. 2008;76:318-328.
18. Gooding P, Tarrier N. A systematic review and meta-analysis of cognitive-behavioural interventions to reduce problem gambling: hedging our bets? Behav Res Ther. 2009;47:592-607.
19. Petry NM, Ammerman Y, Bohl J, et al. Cognitive-behavioral therapy for pathological gamblers. J Consult Clin Psychol. 2006;74:555-567.
20. Ladouceur R, Lachance S, Fournier PM. Is control a viable goal in the treatment of pathological gambling? Behav Res Ther. 2009;47:189-197.
21. Oei TP, Gordon LM. Psychosocial factors related to gambling abstinence and relapse in members of gamblers anonymous. J Gambl Stud. 2008;24:91-105.
22.Petry NM. Gamblers anonymous and cognitive-behavioral therapies for pathological gamblers. J Gambl Stud. 2005;21:27-33.
23. Iancu I, Lowengrub K, Dembinsky Y, et al. Pathological gambling: an update on neuropathophysiology and pharmacotherapy [published correction appears in CNS Drugs. 2008;22:406]. CNS Drugs. 2008;22:123-138.
24. Lowengrub K, Iancu I, Aizer A, et al. Pharmacotherapy of pathological gambling: review of new treatment modalities. Expert Rev Neurother. 2006;6: 1845-1851.
25. Grant JE, Brewer JA, Potenza MN. The neurobiology of substance and behavioral addictions. CNS Spectr. 2006;11:924-930.
26. Toneatto T, Brands B, Selby P. A randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of concurrent alcohol use disorder and pathological gambling. Am J Addict. 2009;18:219-225.
27. Grant JE, Kim SW, Hollander E, Potenza MN. Predicting response to opiate antagonists and placebo in the treatment of pathological gambling. Psychopharmacology (Berl). 2008;200:521-527.
28. Grant JE, Kim SW, Hartman BK. A double-blind, placebo-controlled study of the opiate antagonist naltrexone in the treatment of pathological gambling urges. J Clin Psychiatry. 2008;69:783-789.
29. Grant JE, Potenza MN, Hollander E, et al. Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling. Am J Psychiatry. 2006;163:303-312.
30. Grant JE, Kim SW. Effectiveness of pharmacotherapy for pathological gambling: a chart review. Ann Clin Psychiatry. 2002;14:155-161.
31. Black DW, Arndt S, Coryell WH, et al. Bupropion in the treatment of pathological gambling: a randomized, double-blind, placebo-controlled, flexible-dose study. J Clin Psychopharmacol. 2007;27:143-150.
32. Padala PR, Madaan V, Sattar SP. Bupropion therapy for pathological gambling. Ann Pharmacother. 2007;41:529.
33. Dannon PN, Lowengrub K, Musin E, et al. Sustained-release bupropion versus naltrexone in the treatment of pathological gambling: a preliminary blind-rater study. J Clin Psychopharmacol. 2005;25: 593-596.
34. Leung KS, Cottler LB. Treatment of pathological gambling. Curr Opin Psychiatry. 2009;22:69-74.
35. Hollander E, Pallanti S, Allen A, et al. Does sustained-release lithium reduce impulsive gambling and affective instability versus placebo in pathological gamblers with bipolar spectrum disorders? Am J Psychiatry. 2005;162:137-145.
36. McElroy SL, Nelson EB, Welge JA, et al. Olanza-pine in the treatment of pathological gambling: a negative randomized placebo-controlled trial. J Clin Psychiatry. 2008;69:433-440.
37. Fong T, Kalechstein A, Bernhard B, et al. A double-blind, placebo-controlled trial of olanzapine for the treatment of video poker pathological gamblers. Pharmacol Biochem Behav. 2008;89:298-303.
38. Sevincok L, Akoglu A, Akyol A. Quetiapine in a case with Parkinson disease and pathological gambling. J Clin Psychopharmacol. 2007;27:107-108.
39. Zack M, Poulos C. Effects of the atypical stimulant modafinil on a brief gambling episode in pathological gamblers with high vs low impulsivity. J Psychopharmacol. 2009;23:660-671.
40. Grant JE, Kim SW, Odlaug BL. N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study. Biol Psychiatry. 2007;62:652-657.
41. Volkow ND, Fowler JS, Logan J, et al. Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA. 2009;301:1148-1154.
42. Ingle PJ, Marotta J, McMillan G, Wisdom JP. Significant others and gambling treatment outcomes. J Gambl Stud. 2008;24:381-392.
43. Stinchfield R. Reliability, validity, and classification accuracy of the South Oaks Gambling Screen (SOGS). Addict Behav. 2002;27:1-19.
44. Hodgins DC. Using the NORC DSM Screen for Gambling Problems as an outcome measure for pathological gambling: psychometric evaluation. Addict Behav. 2004;29:1685-1690.
45. Wickwire EM Jr, Burke RS, Brown SA, et al. Psychometric evaluation of the National Opinion Research Center DSM-IV Screen for Gambling Problems (NODS). Am J Addict. 2008;17:392-395.
46. Young M, Stevens M. SOGS and CGPI: parallel comparison on a diverse population. J Gambl Stud. 2008;24:337-356.